OncoArendi Therapeutics SA (PL:MOC)
:MOC
MOC Stock Chart & Stats
zł5.11
--
Market closed
zł5.11
--
Day’s Range― - ―
52-Week Rangezł4.98 - zł9.06
Previous CloseN/A
VolumeN/A
Average Volume (3M)22.76K
Market Cap
zł105.28M
Enterprise Valuezł94.43M
Total Cash (Recent Filing)zł16.35M
Total Debt (Recent Filing)zł5.29M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding20,603,155
10 Day Avg. Volume10,308
30 Day Avg. Volume22,764
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.54
Price to Sales (P/S)0.00
P/FCF Ratio-6.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)zł15.00M
MOC FAQ
What was OncoArendi Therapeutics SA’s price range in the past 12 months?
OncoArendi Therapeutics SA lowest stock price was zł4.98 and its highest was zł9.06 in the past 12 months.
What is OncoArendi Therapeutics SA’s market cap?
OncoArendi Therapeutics SA’s market cap is zł105.28M.
When is OncoArendi Therapeutics SA’s upcoming earnings report date?
OncoArendi Therapeutics SA’s upcoming earnings report date is Apr 30, 2026 which is in 15 days.
How were OncoArendi Therapeutics SA’s earnings last quarter?
OncoArendi Therapeutics SA released its earnings results on Mar 31, 2026. The company reported -zł0.084 earnings per share for the quarter, missing the consensus estimate of N/A by -zł0.084.
Is OncoArendi Therapeutics SA overvalued?
According to Wall Street analysts OncoArendi Therapeutics SA’s price is currently Overvalued.
Does OncoArendi Therapeutics SA pay dividends?
OncoArendi Therapeutics SA does not currently pay dividends.
What is OncoArendi Therapeutics SA’s EPS estimate?
OncoArendi Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoArendi Therapeutics SA have?
OncoArendi Therapeutics SA has 20,603,155 shares outstanding.
What happened to OncoArendi Therapeutics SA’s price movement after its last earnings report?
OncoArendi Therapeutics SA reported an EPS of -zł0.084 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.194%.
Which hedge fund is a major shareholder of OncoArendi Therapeutics SA?
Currently, no hedge funds are holding shares in PL:MOC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OncoArendi Therapeutics SA
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.